悟喜生活(08148)发布公告，于2025年8月29日(交易时段后)，公司与配售代理订立配售协议，据此，公 司已有条件同意透过配售代理按竭尽所能基准以每股配售股份0.59港元的配售价配售最多7635.84万股配 售股份予不少于6名承配人，而有关承配人与其最终实益拥有人将为独立第三方。每股配售股份0.59港 元的配售价较股份于最后交易日在联交所所报之收市价每股股份0.73港元折让约19.18%。 假设所有配售股份获悉数配售，配售事项所得款项总额将约为4510万港元，而配售事项所得款项净额 (经扣除配售事项的配售佣金及其他开支后)将约为4400万港元。净价格约为每股配售股份0.576港元。公 司拟按以下方式动用所得款项净额：不少于70%用于扩展集团的产品销售业务;及余下用作集团一般营 运资金。 ...

配售事项所得款项净额估计约为港币1.307亿元。 裕承科金(00279)发布公告，于2025年8月29日(交易时段后)，公司与配售代理订立配售协议，据此，公 司同意透过配售代理按尽力基准以配售价每股配售股份港币0.690元向不少于六名承配人配售最多1.91亿 股配售股份。 配售价较于2025年8月29日(即配售协议日期)在联交所所报收市价每股股份港币0.850元折让约18.8%。 ...

募集资金将用于：产品研发与升级，提升技术和解决方案能力。产品商业化及业务发展，加强外部合作 以扩大公司规模和市场份额。潜在的收购投资、人才吸引、营运资金补充及一般公司用途。 晶泰控股公布，公司已与配售代理签订配售协议，计划以每股9.28港元的配售价，配售最多约2.86亿股 股份。若配售成功，公司预计净筹约26.3亿港元。 （文章来源：证券时报网） ...

Core Viewpoint - The company, 科笛-B (02487), has announced a share placement agreement to issue approximately 28.9 million shares at a price of HKD 8.40 per share, representing about 9.05% of its existing shares, with the net proceeds expected to be around HKD 240 million [1] Group 1: Share Placement Details - The placement price of HKD 8.40 per share reflects a discount of approximately 12.04% compared to the closing price of HKD 9.55 on the announcement date [1] - The share placement is facilitated by placement agents who will act on behalf of the company [1] Group 2: Use of Proceeds - Approximately 45% of the net proceeds will be allocated for clinical research and trials related to local fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [1] - Another 45% of the net proceeds will be used for marketing activities, channel expansion, and brand building for CU-40102 (a topical finasteride spray) and CU-10201 (a topical 4% minocycline foam) [1] - The remaining 10% of the net proceeds will be utilized for working capital and other general corporate purposes [1]

Core Viewpoint - The company, 科笛-B (02487), has entered into a placement agreement to issue 28.904 million shares at a price of HKD 8.40 per share, representing approximately 9.05% of the company's issued shares as of the announcement date, with a discount of about 12.04% compared to the closing price of HKD 9.55 on August 28, 2025 [1] Summary by Categories Placement Details - The placement agreement was signed with placement agents on August 28, 2025, to facilitate the subscription of shares at HKD 8.40 each [1] - The total number of shares to be placed is 28.904 million, which is about 9.05% of the company's issued shares excluding treasury shares [1] - The placement price represents a discount of approximately 12.04% from the closing price on the same day [1] Expected Net Proceeds - The estimated net proceeds from the placement are approximately HKD 240 million after deducting related expenses and costs [1] Use of Proceeds - About 45% of the net proceeds will be allocated for clinical research and trials related to localized fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [1] - Another 45% will be used for marketing activities, channel expansion, and brand building for CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam) [1] - Approximately 10% of the net proceeds will be utilized for working capital and other general corporate purposes [1]

Core Viewpoint - The company, Rongzhi Holdings (06080.HK), announced a placement agreement to issue up to 186.6 million shares, representing approximately 19.98% of the existing issued share capital as of the announcement date, and about 16.66% of the enlarged issued share capital after the placement [1] Summary by Relevant Sections - **Placement Details** - The placement price is set at HKD 0.085 per share, which is a discount of approximately 15.84% compared to the closing price of HKD 0.101 per share on the date of the placement agreement [1] - The maximum net proceeds from the placement are expected to be around HKD 15.2 million [1] - **Use of Proceeds** - The proceeds from the placement will be utilized for working capital and future business opportunities [1]

配售事项的最高所得款项总额将约为297.0百万港元，而最高所得款项净额将约为293.7百万港元。配售 事项所得款项净额预期将悉数用于偿还集团借贷及用作集团一般营运资金。 格隆汇8月26日丨中泽丰(01282.HK)发布公告，于2025年8月26日，公司与配售代理订立配售协议，据 此，公司已有条件同意透过配售代理，按竭诚基准按每股配售股份0.128港元（较配售协议日期在联交 所所报收市价每股股份0.152港元折让约15.8%）的价格向不少于六名承配人配售最多23.2亿股配售股 份。 配售股份的最高数目相当于(i)本公告日期公司现有已发行股本约86.6%；及(ii)经配售事项扩大的公司已 发行股本约46.4%。 ...

最高所得款项净额将约为2.94亿港元。配售事项所得款项净额预期将悉数用于偿还集团借贷及用作集团 一般营运资金。 中泽丰(01282)发布公告，于2025年8月26日交易时段后，公司与配售代理订立配售协议，据此，公司已 有条件同意透过配售代理，按竭诚基准按每股配售股份0.128港元的价格向不少于六名承配人配售最多 23.2亿股配售股份。配售价较于配售协议日期在联交所所报的收市价每股股份0.152港元折让约15.8%。 ...

Core Viewpoint - The company has announced a placement agreement with a placement agent to issue up to 145 million shares at a price of HKD 0.415 per share, representing a discount of approximately 9.78% from the closing price of HKD 0.46 on August 21, 2025 [1] Group 1 - The placement is aimed at attracting at least six independent third-party subscribers [1] - If fully subscribed, the 145 million shares will account for about 6.34% of the company's enlarged issued share capital [1] - The total expected proceeds from the placement are approximately HKD 60.175 million, with net proceeds estimated at around HKD 58.825 million after deducting related expenses [1]

Group 1 - The company, WanGuo Gold Group (03939), has announced an agreement for a share placement involving the sale of 22.5 million shares at a price of HKD 32.55 per share [1][2] - The total number of shares being sold represents approximately 2.03% of the company's enlarged issued share capital post-subscription [2] - The subscription price reflects a discount of about 7.00% compared to the closing price of HKD 35.00 per share on August 20, 2025 [2] Group 2 - The estimated net proceeds from the subscription are approximately HKD 722 million after deducting professional fees and expenses [2] - The company intends to use the net proceeds for exploration and development projects related to the Jinling Mine, as well as for general working capital [2]